v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 9 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities        
Net loss from operations $ (6,758,547) $ (7,912,922) $ (23,658,438) $ (16,930,289)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:        
Depreciation and amortization 716,557 2,635,560 3,678,786 3,481,748
Non-cash loss on the sale of Infusionz and select assets, net     0 2,212,542
Gain on the sale of VitaMedica and income from discontinued operations     (1,948,538) 0
Loss on the sale of New England Technology     1,737,326 0
Amortization of loan costs 11,868 81,602 115,787 62,408
Amortization of consideration discount 358,038 900,339 1,112,676 969,098
Change in deferred tax asset 0 (2,668,769) (344,802) (3,139,227)
Inventory write off for Amazon Inventory 499,924 0    
Provision for credit losses for Amazon receivable 554,260 0    
Reduction of acquisition payable (152,500)      
Unrealized (gain) loss on digital assets 5,268 0    
Lease impairment (gain on settlement) (269,994) 0    
Impairment of goodwill and intangible assets     7,869,425 3,746,301
Inventory write-offs 418,030 67,928 1,812,319 118,990
Loss on impairment of building     336,434 0
Loss on sale of assets related to relocation of facility     569,195  
Gain on sale of interactive offers     (237,670) 0
Noncontrolling interest     0 (559,967)
Change in derivative     0 1,770
Stock based compensation 695,229 965,229 1,169,843 3,664,538
Changes in assets and liabilities, net of acquired amounts        
Accounts receivable (128,272) 459,747 675,709 (364,665)
Inventory (392,908) 2,251,230 2,651,252 (1,366,269)
Prepaid expenses and other assets 491,578 642,111 106,610 287,797
Operating lease payable 23,794 301,492 302,050 4,238
Accounts payable and accrued liabilities 419,700 (1,333,894) (944,020) 389,458
Deferred revenue (211,341) (22,431) 101,305 0
Net cash used in by operating activities - Continuing Operations (4,137,346) (3,700,706) (4,894,751) (7,421,529)
Net cash provided by operating activities - Discontinued Operations 0 879,614 4,793,374 7,624,206
Net cash used in operating activities (4,137,346) (2,821,092) (101,377) 202,677
Cash flows from investing activities        
Acquisition of Lucky Tail     0 (3,528,239)
Proceeds from the sale of the building, net 4,005,516 0 2,100,000 0
Proceeds from the sale of E-core 2,000,000 0    
Proceeds from the sale of Interactive Offers, net of liabilities paid 0 147,592 203,025 0
Acquisition and sale of digital assets (50,000)      
Acquisition of Cygnet Online LLC, net 0 (500,000) (539,348) (1,050,000)
Proceeds from the sale of Infusionz and selected assets     0 5,492,532
Acquisition of property and equipment (197,999) (663,057) (932,565) (937,564)
Net cash provided by (used in) investing activities - Continuing Operations 5,757,517 (1,015,465) 831,112 (23,271)
Net cash (used in) investing activities - Discontinued Operations 0 (70,000) (4,206,823) (2,551,587)
Net cash provided by (used in) investing activities 5,757,517 (1,085,465) (3,375,711) (2,574,858)
Cash flows from financing activities        
Repayment of the senior convertible notes payable     0 (6,305,406)
Proceeds from the issuance of stock     0 6,127,893
Payment on acquisition notes payable 0 (280,972) (246,761) (751,152)
Proceeds from related party advance     100,000 0
Payment on acquisition notes payable for E-core 0 (3,184,089)    
Issuance of preferred stock series A 325,000 0    
Repayment of Cygnet notes payable (66,656) 0    
Proceeds from related party advance 75,000 0    
Proceeds from convertible note payable     0 2,650,000
Proceeds from issuance of convertible notes 350,000 0    
Repayment of related party advance (100,000) 0    
Proceeds on note payable on building     0 3,000,000
Repayment on note payable on building (2,634,538) (180,887) (207,028) (158,434)
Proceeds on note payable, related party     0 1,470,000
Net cash used in financing activities - Continuing Operations (2,051,194) (3,645,948) (353,789) 6,032,901
Net cash (used in) provided by financing activities - Discontinued Operations 0 3,284,532 0 (6,318,234)
Net cash used in financing activities (2,051,194) (361,416) (353,789) (285,333)
Net (decrease) increase in cash - Discontinued Operations 0 4,094,146 586,551 (1,245,615)
Net decrease in cash - Continuing Operations (431,023) (8,362,119) (4,417,428) (1,411,899)
Cash, beginning of period 661,415 4,492,292 4,492,292 7,149,806
Cash, end of period 230,392 224,318 661,415 4,492,292
Supplemental Cash Flow Disclosures        
Interest paid 329,102 1,505,162 839,000 2,278,292
Income tax paid 0 0 0 0
Non-cash Investing and Financing Activities        
Issuance of common stock for acquisition of Cygnet 0 162,727 162,727 0
Issuance of common stock for the repayment of convertible note payable 850,000 500,000 500,000 0
Issuance of debt for acquisition of Cygnet 0 300,000 300,000 0
Bloomios non-cash payment of receivables, net $ 0 $ 845,443 845,443 0
Non-cash proceeds in the sale of VitaMedica     1,900,000 0
Issuance of stock for services     0 140,700
Issuance of stock for interest expense     0 607,004
Liabilities assumed from acquisition of E-Core     0 (7,712,168)
Issuance of stock for acquisition of E-Core     0 6,000,000
Assets available for sale     $ 0 $ 1,026,043